|
1
|
Damassi A, Cremante M, Signori A, Rebuzzi SE, Malgeri A, Napoli MD, Caffo O, Vignani F, Cavo A, Roviello G, Prati V, Tudini M, Atzori F, Messina M, Morelli F, Prati G, Nolè F, Catalano F, Murianni V, Rescigno P, Banna GL, Fornarini G, Buti S. Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. Immunotherapy 2024:1-9. [PMID: 39155821 DOI: 10.1080/1750743x.2024.2385881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Accepted: 07/25/2024] [Indexed: 08/20/2024] Open
Abstract
Aim: To define the prognostic significance of first-line TKI in mRCC patients receiving nivolumab.Materials and methods: A total of 571 mRCC patients who received ≥second line nivolumab were included in this subanalysis. The correlation between prior TKI (sunitinib vs. pazopanib) and overall response rate (ORR), disease control rate, progression-free survival and overall survival were investigated. Additionally, the impact of TKI choice according to the International Metastatic RCC Database Consortium prognostic score was examined.Results: There was no significant difference between sunitinib and pazopanib groups in terms of mPFS, mOS, overall response rate and disease control rate. Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score.Conclusion: There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.
Collapse
Affiliation(s)
- Alessandra Damassi
- Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy
| | - Malvina Cremante
- Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy
| | - Alessio Signori
- Department of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, Genova, 16132, Italy
| | - Sara Elena Rebuzzi
- Medical Oncology Unit, Ospedale San Paolo, Savona, 17100, Italy
- Department of Internal Medicine & Medical Specialties (Di.M.I.), University of Genova, Genova, 16132, Italy
| | - Andrea Malgeri
- Department of Medical Oncology, Università Campus Biomedico of Roma, Rome, 00128, Italy
| | - Marilena Di Napoli
- Department of Urology & Gynecology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Napoli, 80131, Italy
| | - Orazio Caffo
- Medical Oncology Department, Ospedale Santa Chiara - APSS, Trento, 38122, Italy
| | - Francesca Vignani
- Division of Medical Oncology, Ordine Mauriziano Hospital, Torino, 10128, Italy
| | - Alessia Cavo
- Oncology Unit, Villa Scassi Hospital, Genova, 16149, Italy
| | - Giandomenico Roviello
- Department of Health Sciences, Section of Clinical Pharmacology & Oncology, University of Firenze, Firenze, 50139, Italy
| | - Veronica Prati
- Department of Medical Oncology, Ospedale Michele e Pietro Ferrero, Verduno-Azienda Sanitaria Locale CN2, Verduno, 12060, Italy
| | - Marianna Tudini
- Medical Oncology, St. Salvatore Hospital, L'Aquila, 67100, Italy
| | - Francesco Atzori
- SSD Oncologia Medica, Ospedale Sirai di Carbonia, ASL Sulcis, 09013, Italy
| | - Marco Messina
- Medical Oncology, Ospedale Civico (A.R.N.A.S.), Palermo, 90127, Italy
| | - Franco Morelli
- Oncology department, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, 71013, Italy
| | - Giuseppe Prati
- Department of Oncology & Advances Technologies, IRCCS - AUSL Reggio Emilia, Guastalla, 41016, Italy
| | - Franco Nolè
- Medical Oncology Division of Urogenital & Head & Neck Tumors, IEO, European Institute of Oncology IRCCS, Milan, 20141, Italy
| | - Fabio Catalano
- Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy
| | - Veronica Murianni
- Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy
| | - Pasquale Rescigno
- Translational & Clinical Research Institute, Centre for Cancer, Newcastle University, Newcastle Upon Tyne, NE7 7DN, United Kingdom
- Candiolo Cancer Institute, FPO-IRCCS,Candiolo, 10060, Italy
| | - Giuseppe Luigi Banna
- Portsmouth Hospitals University NHS Trust, Portsmouth, PO6 3LY, United Kingdom
- Faculty of Science & Health, School of Pharmacy & Biomedical Sciences, University of Portsmouth, Portsmouth, PO1 2UP, United Kingdom
| | - Giuseppe Fornarini
- Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, 16132, Italy
| | - Sebastiano Buti
- Medical Oncology Unit, University Hospital of Parma, Parma, 43126, Italy
- Department of Medicine & Surgery, University of Parma, Parma, 43121, Italy
| |
Collapse
|
|
2
|
Monti M, Lunardini S, Magli IA, Campi R, Primiceri G, Berardinelli F, Amparore D, Terracciano D, Lucarelli G, Schips L, Ferro M, Marchioni M. Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature. Biomedicines 2022; 10:biomedicines10061287. [PMID: 35740309 PMCID: PMC9220270 DOI: 10.3390/biomedicines10061287] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 05/17/2022] [Accepted: 05/24/2022] [Indexed: 12/17/2022] Open
Abstract
Locally advanced or metastatic renal cell carcinomas (mRCCs) account for up to 15% of all kidney cancer diagnoses. Systemic therapies (with or without surgery) represent gold standard treatments, mostly based on tyrosine kinase inhibitors in association with immunotherapy. We provide an overview of the current knowledge of miRNAs as predictors of treatment resistance. A systematic review of the literature was carried out in January 2022 following the PICO methodology. Overall, we included seven studies—four testing plasmatic miRNAs, two exosomal miRNAs, and one urinary miRNA. A total of 789 patients were included (354 for plasmatic miRNAs, 366 for urinary miRNAs, and 69 for exosomal miRNAs). Several miRNAs were tested within the included studies, but six plasmatic (miR9-5-p¸ miR-192, miR193-3p, miR-501-3p¸ miR-221, miR-376b-3p) one urinary (miR-30a-5p), and three exosomal (miR-35-5p, miR-301a-3p, miR-1293) were associated with resistance to systemic treatments or treatment failure in mRCC patients. Results showed a fair accuracy of these biomarkers in predicting treatment resistance and overall survival. However, to date, the biomarkers tested have not been validated and their clinical uses are not recommended. Nevertheless, the literature results are encouraging; future large clinical trials are warranted to validate the effectiveness of these tools in clinical decision-making.
Collapse
Affiliation(s)
- Martina Monti
- Department of Medical Oral and Biotechnological Science, “G. d’Annunzio” University of Chieti and Pescara, 66100 Chieti, Italy; (M.M.); (S.L.); (I.A.M.); (G.P.); (F.B.); (L.S.); (M.M.)
| | - Susanna Lunardini
- Department of Medical Oral and Biotechnological Science, “G. d’Annunzio” University of Chieti and Pescara, 66100 Chieti, Italy; (M.M.); (S.L.); (I.A.M.); (G.P.); (F.B.); (L.S.); (M.M.)
| | - Igino Andrea Magli
- Department of Medical Oral and Biotechnological Science, “G. d’Annunzio” University of Chieti and Pescara, 66100 Chieti, Italy; (M.M.); (S.L.); (I.A.M.); (G.P.); (F.B.); (L.S.); (M.M.)
| | - Riccardo Campi
- Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, 50134 Florence, Italy;
| | - Giulia Primiceri
- Department of Medical Oral and Biotechnological Science, “G. d’Annunzio” University of Chieti and Pescara, 66100 Chieti, Italy; (M.M.); (S.L.); (I.A.M.); (G.P.); (F.B.); (L.S.); (M.M.)
| | - Francesco Berardinelli
- Department of Medical Oral and Biotechnological Science, “G. d’Annunzio” University of Chieti and Pescara, 66100 Chieti, Italy; (M.M.); (S.L.); (I.A.M.); (G.P.); (F.B.); (L.S.); (M.M.)
| | - Daniele Amparore
- Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Orbassano, 10124 Turin, Italy;
| | - Daniela Terracciano
- Department of Translational Medical Sciences, University ‘Federico II’, 80138 Naples, Italy;
| | - Giuseppe Lucarelli
- Department of Emergency & Organ Transplantation—Urology, Andrology & Kidney Transplantation Unit, University of Bari, 70121 Bari, Italy;
| | - Luigi Schips
- Department of Medical Oral and Biotechnological Science, “G. d’Annunzio” University of Chieti and Pescara, 66100 Chieti, Italy; (M.M.); (S.L.); (I.A.M.); (G.P.); (F.B.); (L.S.); (M.M.)
| | - Matteo Ferro
- Division of Urology, European Institute of Oncology, IRCCS, 10060 Milan, Italy
- Correspondence:
| | - Michele Marchioni
- Department of Medical Oral and Biotechnological Science, “G. d’Annunzio” University of Chieti and Pescara, 66100 Chieti, Italy; (M.M.); (S.L.); (I.A.M.); (G.P.); (F.B.); (L.S.); (M.M.)
| |
Collapse
|
|
3
|
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol 2022; 15:61. [PMID: 35585567 PMCID: PMC9118588 DOI: 10.1186/s13045-022-01282-8] [Citation(s) in RCA: 170] [Impact Index Per Article: 85.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Accepted: 05/03/2022] [Indexed: 02/08/2023] Open
Abstract
Immunotherapies like the adoptive transfer of gene-engineered T cells and immune checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some patients are refractory or resistant to these therapies, and the mechanisms underlying tumor immune resistance have not been fully elucidated. Immunosuppressive cells such as myeloid-derived suppressive cells, tumor-associated macrophages, tumor-associated neutrophils, regulatory T cells (Tregs), and tumor-associated dendritic cells are critical factors correlated with immune resistance. In addition, cytokines and factors secreted by tumor cells or these immunosuppressive cells also mediate the tumor progression and immune escape of cancers. Thus, targeting these immunosuppressive cells and the related signals is the promising therapy to improve the efficacy of immunotherapies and reverse the immune resistance. However, even with certain success in preclinical studies or in some specific types of cancer, large perspectives are unknown for these immunosuppressive cells, and the related therapies have undesirable outcomes for clinical patients. In this review, we comprehensively summarized the phenotype, function, and potential therapeutic targets of these immunosuppressive cells in the tumor microenvironment.
Collapse
|
|
4
|
Oudard S, Benhamouda N, Escudier B, Ravel P, Tran T, Levionnois E, Negrier S, Barthelemy P, Berdah JF, Gross-Goupil M, Sternberg CN, Bono P, Porta C, Giorgi UD, Parikh O, Hawkins R, Highley M, Wilke J, Decker T, Tanchot C, Gey A, Terme M, Tartour E. Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. Cells 2021; 11:17. [PMID: 35011579 PMCID: PMC8750389 DOI: 10.3390/cells11010017] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2021] [Revised: 12/06/2021] [Accepted: 12/16/2021] [Indexed: 12/12/2022] Open
Abstract
The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1+CD14 and Tie2+CD14) was analyzed in an ancillary study from the prospective PazopanIb versus Sunitinib patient preferenCE Study (PISCES) (NCT01064310), where metastatic renal cell carcinoma (mRCC) patients were treated with two anti-angiogenic drugs, either sunitinib or pazopanib. Blood samples from 86 patients were collected prospectively at baseline (T1), and at 10 weeks (T2) and 20 weeks (T3) after starting anti-angiogenic therapy. Various subpopulations of myeloid cells (monocytes, VEGFR-1+CD14 and Tie2+CD14 cells) decreased during treatment. When patients were divided into two subgroups with a decrease (defined as a >20% reduction from baseline value) (group 1) or not (group 2) at T3 for VEGFR-1+CD14 cells, group 1 patients presented a median PFS and OS of 24 months and 37 months, respectively, compared with a median PFS of 9 months (p = 0.032) and a median OS of 16 months (p = 0.033) in group 2 patients. The reduction in Tie2+CD14 at T3 predicted a benefit in OS at 18 months after therapy (p = 0.04). In conclusion, in this prospective clinical trial, a significant decrease in subpopulations of pro-angiogenic monocytes was associated with clinical response to anti-angiogenic drugs in patients with mRCC.
Collapse
Affiliation(s)
- Stephane Oudard
- APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France; (N.B.); (T.T.); (E.L.); (C.T.); (A.G.); (M.T.)
- APHP, Service de Cancérologie, Hôpital Européen Georges Pompidou, Université de Paris, 75908 Paris, France
| | - Nadine Benhamouda
- APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France; (N.B.); (T.T.); (E.L.); (C.T.); (A.G.); (M.T.)
| | - Bernard Escudier
- Department of Medical Oncology, Institut Gustave Roussy, CEDEX, 94805 Villejuif, France;
| | - Patrice Ravel
- Cancer Bioinformatics and Systems Biology, Institut de Recherche en Cancérologie de Montpellier, Campus Val d’Aurelle, Université Montpellier, CEDEX 5, 34298 Montpellier, France;
| | - Thi Tran
- APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France; (N.B.); (T.T.); (E.L.); (C.T.); (A.G.); (M.T.)
| | - Emeline Levionnois
- APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France; (N.B.); (T.T.); (E.L.); (C.T.); (A.G.); (M.T.)
| | - Sylvie Negrier
- Centre Léon Bérard Lyon, University Lyon 1, 69008 Lyon, France;
| | - Philippe Barthelemy
- Institut de Cancérologie Strasbourg Europe, Strasbourg University Hospital, 67200 Strasbourg, France;
| | - Jean François Berdah
- Medical Oncology Unit, Hôpital Privé Toulon-Hyères, Sainte-Marguerite, 83400 Hyeres, France;
| | - Marine Gross-Goupil
- Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, 31000 Bordeaux, France;
| | - Cora N. Sternberg
- Englander Institute for Precision Medicine, Weill Cornell Medicine, Sandra and Edward Meyer Cancer, New York, NY 10065, USA;
| | - Petri Bono
- Kamppi Hospital Department, Terveystalo Finland, 00100 Helsinki, Finland;
| | - Camillo Porta
- Division of Translational Oncology, IRCCS San Matteo University Hospital, 27100 Pavia, Italy;
- Division of Oncology, Policlinico Consorziale di Bari, University of Bari ‘A. Moro’, 70121 Bari, Italy
| | - Ugo De Giorgi
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, 47014 Meldola, Italy;
| | - Omi Parikh
- Department of Oncology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston PR2 9HT, UK;
| | - Robert Hawkins
- Institute of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK;
| | - Martin Highley
- Oncology Centre, Derriford Hospital, Plymouth PL6 8DH, UK;
| | - Jochen Wilke
- Gemeinschaftspraxis Dres. Wilke/Wagner/Petzoldt, 90766 Fuerth, Germany;
| | - Thomas Decker
- Studienzentrum Onkologie, Practice for Hematology and Oncology, 88212 Ravensburg, Germany;
| | - Corinne Tanchot
- APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France; (N.B.); (T.T.); (E.L.); (C.T.); (A.G.); (M.T.)
| | - Alain Gey
- APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France; (N.B.); (T.T.); (E.L.); (C.T.); (A.G.); (M.T.)
| | - Magali Terme
- APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France; (N.B.); (T.T.); (E.L.); (C.T.); (A.G.); (M.T.)
| | - Eric Tartour
- APHP, Hôpital Européen Georges Pompidou, INSERM U970, PARCC, Université de Paris, 75020 Paris, France; (N.B.); (T.T.); (E.L.); (C.T.); (A.G.); (M.T.)
| |
Collapse
|